Effects of extensive and poor gastrointestinal metabolism on the pharmacodynamics of pravastatin

Journal of Clinical Pharmacology

Volumn 38, Issue 4, 1998, Pages 331-336

  Ito, Matthew K ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; DRUG METABOLITE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SQ 31906; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; GASTROINTESTINAL TRACT; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS;

EID: 0031923790     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04432.x     Document Type: Article

References (17)

1. Pan HY, Triscari J, DeVault AR, Smith SA, Wang-Iverson D, Swanson BN, Willard DA: Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol 1990;31:665-670.
2. Halstenson CE, Triscari J, DeVault A, Shapiro B, Keane W, Pan HY: Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 1992;32:124-132.
3. Pan HY: Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 1991; 40(suppl 1):S15-S18.
4. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH: Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991;19:740-748.
5. Triscari J, O'Donnell D, Zinny M, Pan HY: Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol 1995;35:142-144.
6. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH: Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991;19:740-748.
7. Trinder P: Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969;6:24-27.
8. ++ precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin Chem 1982;28:1379-1388.
9. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
10. Funke PT, Ivashkiv E, Arnold ME, Cohen AL: Determination of pravastatin sodium and its major metabolites in human serum plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom 1989;18:904-909.
11. Leitersdorf E, Eisenberg S, Eliav O, Friedlander Y, Berkman N, Dann EJ, et al: Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993;87(suppl III):III35-III44.
12. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA: Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990; 30:1128-1135.
13. Greiff JMC, Rowbotham D: Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet 1994;27:447-461.
14. Yavorski RT, Hallgren SE, Blue PW: Effects of verapamil and diltiazem on gastric emptying in normal subjects. Dig Dis Sci 1991;36:1274-1276.
15. Santander R, Mena I, Gramisu M, Valenzuela JE: Effect of nifedipine on gastric emptying and gastrointestinal motility in man. Dig Dis Sci 1988;55:535-539.
16. Traube M, Lange RC, McAllister RG, McCallum RW: Effect of nifedipine on gastric emptying in normal subjects. Dig Dis Sci 1985;30:710-712.
17. Hunt BA, Self TH, Lalonde RL, Bottorff MB: Calcium channel blockers as inhibitors of drug metabolism. Chest 1989;96:393-399.